Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

• Status: Completed
• Trial end date: 2021-01-20
• Target enrollment: 0
• Participant gender: All

Summary

To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Olodaterol; Tiotropium Bromide

Criteria

Inclusion criteria:

• Patients who have been started on Vahelva Respimat in accordance with the approved label in Korea

• Age >= 18 years at enrolment

• Patients who have signed on the data release consent form

Exclusion criteria:

• Patients with hypersensitivity to Vahelva Respimat or to any of the excipients.

• Patients with a history of hypersensitivity to atropine or its derivatives(e.g. ipratropium, oxitropium, glycopyrronium, clidinium, umeclidinium)

• Patients with asthma

• Current participation in other clinical trials